Authors:
Dorman, DC
Allen, SL
Byczkowski, JZ
Claudio, L
Fisher, JE
Fisher, JW
Harry, GJ
Li, AA
Makris, SL
Padilla, S
Sultatos, LG
Mileson, BE
Citation: Dc. Dorman et al., Methods to identify and characterize developmental neurotoxicity for humanhealth risk assessment. III: Pharmacokinetic and pharmacodynamic considerations, ENVIR H PER, 109, 2001, pp. 101-111
Authors:
Duggan, ME
Duong, LT
Fisher, JE
Hamill, TG
Hoffman, WF
Huff, JR
Ihle, NC
Leu, CT
Nagy, RM
Perkins, JJ
Rodan, SB
Wesolowski, G
Whitman, DB
Zartman, AE
Rodan, GA
Hartman, GD
Citation: Me. Duggan et al., Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist, J MED CHEM, 43(20), 2000, pp. 3736-3745
Authors:
Langelan, RE
Fisher, JE
Hiruma, K
Palli, SR
Riddiford, LM
Citation: Re. Langelan et al., Patterns of MHR3 expression in the epidermis during a larval molt of the tobacco hornworm Manduca sexta, DEVELOP BIO, 227(2), 2000, pp. 481-494
Citation: At. Rotta et al., Delayed myonecrosis in a leukemic patient with invasive group A streptococcal disease, PEDIAT INF, 18(6), 1999, pp. 564-567
Authors:
Fisher, JE
Rogers, MJ
Halasy, JM
Luckman, SP
Hughes, DE
Masarachia, PJ
Wesolowski, G
Russell, RGG
Rodan, GA
Reszka, AA
Citation: Je. Fisher et al., Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro, P NAS US, 96(1), 1999, pp. 133-138